Starting December 2019, an outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been discovered in Wuhan, China, and then rapidly developed into a worldwide pandemic. As of May 29, 2020, a total of 5,701,337 laboratory-confirmed Coronavirus Disease 2019 (COVID-19) cases had been reported worldwide, with 357,688 deaths confirmed so far. Among the effective control measures to reduce transmission in the community, early reliable laboratory confirmation of SARS-CoV-2 infection is of crucial importance. Here, we summarize advances made in technologies for rapid diagnosis and confirmation of respiratory infections caused by SARS-CoV-2, as well as the selection strategies of testing and sampling sites in SARS-CoV-2 detection.

Since the initial cases with pneumonia of unknown cause reported, viral culture and genetic sequencing of isolates obtained from patients with pneumonia identified a novel coronavirus as the etiology within 10 days in January 2020, benefiting our understanding of disease occurrence and transmission, as well as diagnostic test development ([@bib0065]). Although viral culture is relatively time-consuming and labor-intensive, it's much more useful in the initial phase of emerging epidemics before other diagnostic assays are clinically available. Besides, unbiased, high-throughput sequencing has been proved as a powerful tool for the discovery of pathogens ([Table 1](#tbl0005){ref-type="table"} ). A BGI's detection assay, based on next-generation sequencing, was approved emergency use authorization (EUA) by National Medical Products Administration (NMPA) in China (Table S1). However, whole genome sequencing is time-consuming and requires specialized instruments with high technical thresholds, and thus is not recommended for widespread use in clinical.Table 1Laboratory testing for detection of SARS-CoV-2.Table 1Testing typeSpecimen typeCharacteristicsTesting timeLimitationViral cultureRespiratory sampleGold standard for virus diagnosis and it's useful in the initial phase of emerging epidemics3-7 daysTime and labor consuming, biosafety level 3 laboratory needed, cannot be widely used in clinicalNAAT, whole genome sequencingRespiratory sample and bloodDetecting all pathogens in a given specimen including SARS-CoV-2, as well as viral genome mutations20 hoursTime-consuming, specialized instruments with high technical thresholds, and high costNAAT, real-time RT-PCRRespiratory sample, stool, and bloodMost widely used in laboratory confirmation of SARS-CoV-2 infection1.5-3 hoursTime-consuming procedure, the requirements of biosafety conditions, expensive equipment, skilled personnel, and false negative resultsNAAT, isothermal ampliﬁcationRespiratory sample, stool, and bloodRequiring only a single temperature for amplification that cost less time but comparable performance with real-time RT-PCR free of specialized laboratory equipment0.5-2 hoursFalse negative results as real-time RT-PCRSerological testingSerum, plasma, and bloodLess time required, simple to operate, useful in disease surveillance and epidemiologic research15-45 minsCross-reaction with other subtypes of coronavirusesPoint-of-care testRespiratory sampleProviding rapid actionable information with good sensitivity and speciﬁcity for patient care outside of the clinical diagnostic laboratory5-30 minsRisk of quality loss and lack of cost-effectiveness[^1]

In acute respiratory infection, real-time RT-PCR is routinely used to detect causative viruses from respiratory specimens. WHO recommends that patients who meet the case definition for suspected SARS-CoV-2 should be screened for the virus nucleic acid amplification test ([Table 1](#tbl0005){ref-type="table"}). Various real-time RT-PCR assays for the detection of SARS-CoV-2 RNA have been developed worldwide, with different viral genes or regions targeted (Table S1). To date, 13 and 52 commercial SARS-CoV-2 real-time RT-PCR diagnostic panels have been issued emergency use authorization (EUA) by China and the US, respectively, with the limit of detection (LoD) varying from 100 to 1000 copies/ml (Table S1). Although its relatively high sensitivity of RT-PCR, there have been reports of multiple false negative tests for the same patients infected with SARS-CoV-2 in China ([@bib0050], [@bib0045]), suggesting that negative results do not preclude the presence of SARS-CoV-2 in a clinical specimen. In addition, fluctuating RT-PCR results were observed in several patients that the clinical specimens tested positive for SARS-CoV-2 at first, then turned negative in the following test. But in the final, the results returned to be positive ([@bib0020]). False negative results may be due to the selection of sampling locations, poor sample quality, low viral load of the specimen, incorrect storage, and transportation, as well as laboratory testing conditions and personnel operations. If a highly suspected patient was detected negative for the virus, repeat the nucleic acid ampliﬁcation test, or consider collecting a more suitable sample.

Isothermal ampliﬁcation techniques offer a substitutable choice to real-time RT-PCR with comparable performance ([Table 1](#tbl0005){ref-type="table"}). They cost less time and generally do not need specialized laboratory equipment. These techniques include loop-mediated isothermal ampliﬁcation (LAMP), nucleic acid sequence-based amplification (NASBA), and cross priming amplification (CPA), etc. A recent study suggested that reverse transcription LAMP (RT-LAMP) assay could detect as low as 20 copies of SARS-CoV-2 ORF1ab RNA, with 100% agreement with the commercial real-time RT-PCR in 130 swabs and bronchoalveolar lavage ﬂuid samples ([@bib0055]). Another RT-LAMP assay, targeting the N gene of the virus, displayed a detection limit of 100 RNA copies in 30 min combined with the colorimetric visualization ([@bib0005]). These results suggest that RT-LAMP assays can be applied for a sensitive and speciﬁc early detection method to identify SARS-CoV-2 cases. Currently, several isothermal ampliﬁcation based nucleic acid tests for SARS-CoV-2 detection have received EUAs from China's National Medical Products Administration (NMPA) (Table S1).

Serological assays provide an alternative diagnosis approach for the current rapidly growing demand for rapid diagnosis of suspected patients and asymptomatic infections that the entire test could be completed in a short time, even independent of specific equipment or places. They are suggested to be used either in combination with molecular testing or for additional testing in suspected cases with negative nucleic acid results to improve the detection accuracy of COVID-19. In a study of 397 real-time RT-PCR confirmed COVID-19 patients and 128 virus-negative patients, IgM/IgG assays showed a sensitivity and specificity of 88.66% and 90.63% in blood samples, respectively ([@bib0025]). Combined IgM-IgG tests provided better sensitivity than tests for only IgM or IgG. However, cross-reactivity of the serological assay to other coronaviruses has been observed ([@bib0010]). Besides, serological testing is critically useful in disease surveillance and epidemiologic research. A community seroprevalence study of 863 individuals showed that the prevalence of antibodies to SARS-CoV-2 was 4.65% in Los Angeles County ([@bib0030]). 367,000 people were estimated to be infected with SARS-CoV-2, which is 43.53 times higher than the cumulative number (8,430) of confirmed cases by the time of the survey.

Point-of-care (POC) diagnostic tests provide rapid actionable information for patient care outside of centralized facilities, such as airports, local emergency departments and clinics, and other locations. It has been shown to have an immediate impact on patient management and control of infectious disease epidemics ([@bib0015]). At the time of writing, three detection assays have been issued EUAs for point of care diagnostic of SARS-CoV-2 in the US (Table S1), including Xpert Xpress SARS-CoV-2 test (Cepheid, USA) (real-time RT-PCR assay), ID NOW COVID-19 test (Abbott, USA) (isothermal nucleic acid amplification), Sofia 2 SARS Antigen FIA assay (Quidel, USA) (antigen test). These emerging POC assays would be a powerful tool for effective patient care and outbreak containment of SARS-CoV-2 infection.

Lastly, the selection of specimens for molecular assays is crucial in the laboratory diagnosis of SARS-CoV-2 ([Table 2](#tbl0010){ref-type="table"} ). To prevent misdiagnosis caused by insufficient viral load, BALF is the most preferred specimen as the viral loads of respiratory tract specimens are highest in BALF, followed by sputum, NP swabs, and OP swabs ([@bib0035], [@bib0060]). Due to the prolonged presence of SARS-CoV-2 viral RNA in fecal samples and the potential of fecal-oral transmission, fecal testing for SARS-CoV-2 is highly recommended when virus negativity in respiratory tract specimens ([@bib0040]). In addition, a sampling of different sites in suspected persons or repeatedly sampling at different infected stages may help to prevent false negative results.Table 2Sampling location recommended for patients with COVID-19.Table 2Specimen typePositive rate[\*](#tblfn0005){ref-type="table-fn"}Priority of SpecimenEarly stage/ initial diagnosisAdvanced stageRecovery/ Follow-upRemarksOropharyngeal swab32∼48%![](fx1_lrg.gif)RecommendedRecommendedRecommendedViral loads in the upper respiratory tract peak soon in one week after symptom onset then steadily decline after that.Nasopharyngeal swab63%![](fx2_lrg.gif)Highly recommendedHighly recommendedHighly recommendedNasopharyngeal swab samples generally showed higher viral loads and positive rates than oropharyngeal swab samples.Bronchoalveolar lavage fluid (BALF)79∼93%![](fx3_lrg.gif)Not recommendedHighly recommendedNot recommendedBALF could be collected from patients presenting with more severe disease or undergoing mechanical ventilation.Sputum72∼76%![](fx4_lrg.gif)Highly recommendedHighly recommendedHighly recommendedFor patients who develop a productive cough, sputum should be collected and tested for SARS-CoV-2.Stool/anal swab29%![](fx5_lrg.gif)Not recommendedNot recommendedHighly recommendFecal testing for SARS-CoV-2 is highly recommended after viral clearance in the respiratory samples.[^2]

Overall, we comprehensively review all the available diagnostic assays of SARS-CoV-2 infection, including virus culture, whole genome sequencing, real-time RT-PCR, isothermal amplification, antibody test, and POC test. The choice of a diagnostic assay for COVID-19 should take into full consideration the characteristics and advantages of various technologies, as well as different clinical scenarios and requirements. Moreover, proper collection of specimens is of great importance to improve the detection accuracy of infectious diseases with COVID-19.
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[^1]: NAAT, nucleic acid amplification test

[^2]: All patients were confirmed by SARS-CoV-2 detection (11, 12).
